Search





Search





Markets
/
Stocks
/
nasdaq-nams
/

NewAmsterdam Pharma Company NV

NAMS

Add to Watchlist

35.440USD

-1.440-3.90%

Close 05/15, 16:00（ET）Quotes delayed by 15 min

4.13BMarket Cap

LossP/E TTM



NewAmsterdam Pharma Company NV

35.440

-1.440-3.90%

Overview Financials Discussions Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Discussions

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of NewAmsterdam Pharma Company NV

Currency: USD Updated: 2026-05-15

Key Insights

NewAmsterdam Pharma Company NV's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 12 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 51.21.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

NewAmsterdam Pharma Company NV's Score

Industry at a Glance

Industry Ranking

12 / 382

Overall Ranking

97 / 4482

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

NewAmsterdam Pharma Company NV Highlights

StrengthsRisks

NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 59.71% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 22.50M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 22.50M.

Undervalued

The company’s latest PE is -19.92, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 128.70M shares, increasing 1.86% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 6.76K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.68.

Analyst Rating

Based on 16 analysts

Buy

Current Rating

51.214

Target Price

+38.87%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-05-15

The current financial score of NewAmsterdam Pharma Company NV is 6.31, ranking 257 out of 382 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 3.04M, representing a year-over-year increase of 2.08%, while its net profit experienced a year-over-year increase of 22.55%.

Score

Industry at a Glance

Previous score

6.31

Change



Financials

9.89

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.95

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.84

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

4.80

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.08

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

NewAmsterdam Pharma Company NV's Company Valuation

Currency: USD Updated: 2026-05-15

The current valuation score of NewAmsterdam Pharma Company NV is 6.93, ranking 189 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -19.92, which is -89.66% below the recent high of -2.06 and -27.21% above the recent low of -25.35.

Score

Industry at a Glance

Previous score

6.93

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 12/382

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-05-15

The current earnings forecast score of NewAmsterdam Pharma Company NV is 8.75, ranking 63 out of 382 in the Biotechnology & Medical Research industry. The average price target is 45.00, with a high of 60.00 and a low of 37.00.

Score

Industry at a Glance

Previous score

8.75

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 16 analysts

Buy

Current Rating

51.214

Target Price

+38.87%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

NewAmsterdam Pharma Company NV

NAMS

CRISPR Therapeutics AG

CRSP

Beigene Ltd

ONC

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Ionis Pharmaceuticals Inc

IONS

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-05-15

The current price momentum score of NewAmsterdam Pharma Company NV is 9.00, ranking 38 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 42.48 and the support level at 28.12, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.17

Change

-0.17

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

1.272

Buy

RSI(14)

55.610

Neutral

STOCH(KDJ)(9,3,3)

58.082

Sell

ATR(14)

2.355

Low Volatility

CCI(14)

39.956

Neutral

Williams %R

47.126

Neutral

TRIX(12,20)

0.538

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

37.710

Sell

MA10

35.283

Buy

MA20

32.842

Buy

MA50

32.233

Buy

MA100

33.023

Buy

MA200

32.311

Buy

Institutional Confidence

Currency: USD Updated: 2026-05-15

The current institutional shareholding score of NewAmsterdam Pharma Company NV is 10.00, ranking 1 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 110.09%, representing a quarter-over-quarter increase of 5.56%. The largest institutional shareholder is Andreas Halvorsen, holding a total of 4.20M shares, representing 3.60% of shares outstanding, with 42.15% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Frazier Life Sciences Management, L.P.

16.94M

+1.45%

Capital World Investors

9.98M

+1.64%

RA Capital Management, LP

9.55M

-5.81%

Forbion Capital Partners

9.20M

-0.15%

Fidelity Management & Research Company LLC

5.87M

+8.92%

Bain Capital Life Sciences Investors, LLC

5.67M

-45.83%

Wellington Management Company, LLP

5.03M

+25.20%

Viking Global Investors LP

Star Investors

4.20M

-35.09%

Deerfield Management Company, L.P.

4.16M

-2.39%

Duquesne Family Office LLC

Star Investors

3.07M

+59.60%

Risk Assessment

Currency: USD Updated: 2026-05-15

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of NewAmsterdam Pharma Company NV is 5.78, ranking 37 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 0.07. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.